Monitoring Resistance, Recurrence in NSCLC.
Two studies indicate the importance of serial biopsies in monitoring patients with non-small cell lung cancer. In one, heterogeneous resistance mechanisms to EGFR-targeted therapy were observed, often varying between biopsies for individual patients. In another, circulating tumor cells detected recurrence 6 months earlier, on average, than conventional imaging.